[1]ADAMS LA, LYMP JF, ST SAUVER J, et al.The natural history of nonalcoholic fatty liver disease:a population-based cohort study[J].Gastroenterology, 2005, 129 (1) :113-121.
|
[2]BERLANGA A, GUIU-JURADO E, PORRAS JA, et al.Molecular pathways in non-alcoholic fatty liver disease[J].Clin Exp Gastroenterol, 2014, 7:221-239.
|
[3]FERRE P, FOUFELLE F.Hepatic steatosis:a role for de novo lipogenesis and the transcription factor SREBP-1c[J].Diabetes Obes Metab, 2010, 12 (Suppl 2) :83-92.
|
[4]INUI A, ASAKAWA A, BOWERS CY, et al.Ghrelin, appetite, and gastric motility:the emerging role of the stomach as an endocrine organ[J].FASEB J, 2004, 18 (3) :439-456.
|
[5]BARNETT BP, HWANG Y, TAYLOR MS, et al.Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor[J].Science, 2010, 330 (6011) :1689-1692.
|
[6]TEUFFEL P, WANG L, PRINZ P, et al.Treatment with the ghrelin-O-acyltransferase (GOAT) inhibitor GO-Co A-Tat reduces food intake by reducing meal frequency in rats[J].J Physiol Pharmacol, 2015, 66 (4) :493-503.
|
[7]YANG J, BROWN MS, LIANG G, et al.Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone[J].Cell, 2008, 132 (3) :387-396.
|
[8]GUALILLO O, LAGO F, DIEGUEZ C.Introducing GOAT:a target for obesity and anti-diabetic drugs?[J].Trends Pharmacol Sci, 2008, 29 (8) :398-401.
|
[9]AMIR M, CZAJA MJ.Autophagy in nonalcoholic steatohepatitis[J].Expert Rev Gastroenterol Hepatol, 2011, 5 (2) :159-166.
|
[10]NOUREDDIN M, YATES KP, VAUGHN IA, et al.Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients[J].Hepatology, 2013, 58 (5) :1644-1654.
|
[11]KIM D, CHOI SY, PARK EH, et al.Nonalcoholic fatty liver disease is associated with coronary artery calcification[J].Hepatology, 2012, 56 (2) :605-613.
|
[12]DING ZY, PU L, LU HY, et al.Correlation of liver fat content with serum vitamin A level and insulin resistace in patients with nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2361-2365. (in Chinese) 丁智勇, 卜乐, 鲁鸿燕, 等.非酒精性脂肪性肝病患者血清维生素A水平、肝脏脂肪含量与胰岛素抵抗的相关性分析[J].临床肝胆病杂志, 2017, 33 (12) :2361-2365.
|
[13]NI MM, ZHANG YQ, CHEN YX, et al.Prevalence of nonalcoholic fatty liver disease and its prognostic factors[J].J Clin Hepatol, 2016, 32 (3) :453-458. (in Chinese) 倪曼曼, 张颖秋, 陈岳祥, 等.非酒精性脂肪性肝病患者发病和预后的影响因素分析[J].临床肝胆病杂志, 2016, 32 (3) :453-458.
|
[14]ALKHOURI N, CARTER-KENT C, FELDSTEIN AE.Apoptosis in nonalcoholic fatty liver disease:diagnostic and therapeutic implications[J].Expert Rev Gastroenterol Hepatol, 2011, 5 (2) :201-212.
|
[15]KOEK GH, LIEDORP PR, BAST A.The role of oxidative stress in non-alcoholic steatohepatitis[J].Clin Chim Acta, 2011, 412 (15-16) :1297-1305.
|
[16]YUAN RS, LI H, SUN JH, et al.Lipid-lowering effect and antioxidant activity of polysaccharide from Schisandra Chinensis in rats with non-alcoholic fatty liver disease induced by high-fat diet[J].J Jilin Univ:Med Edit, 2017, 43 (6) :1103-1108. (in Chinese) 苑荣爽, 李贺, 孙靖辉, 等.北五味子多糖对高脂诱导非酒精性脂肪性肝病大鼠的降血脂作用及其抗氧化活性[J].吉林大学学报:医学版, 2017, 43 (6) :1103-1108.
|
[17]JORNAYVAZ FR, SHULMAN GI.Diacylglycerol activation of protein kinase C and hepatic insulin resistance[J].Cell Metabolism, 2012, 15 (5) :574-584.
|
[18]OZCELIK F, YUKSEL C, ARSLAN E, et al.Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance[J].Arch Med Res, 2013, 44 (4) :273-280.
|
[19]MUSSO G, GAMBINO R, BO S, et al.Should non-alcoholic fatty liver disease be included in the definition of metabolic syndrome?A cross-sectional comparison with adult treatment Panel III criteria in nonobese nondiabetic subjects[J].Diabetes Care, 2008, 31 (3) :562-568.
|
[20]RAVIKUMAR B, BERGER Z, RUBINSZTEIN DC, et al.Rapamycin pretreatment protects against apoptosis[J].Hum Mol Genet, 2006, 15 (7) :1209-1216.
|
[21]YU L, Mc PHEE CK, ZHENG L, et al.Termination of autophagy and reformation of lysosomes regulated by Mtor[J].Nature, 2010, 465 (7300) :942-946.
|
[22]LIU HY, HAN J, CAO SY, et al.Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia:inhibition of Fox O1-dependent expression of key autophagy genes by insulin[J].J Biol Chem, 2009, 284 (45) :31484-31492.
|
[23]SINHA RA, FARAH BL, SINGH BK, et al.Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice[J].Hepatology, 2014, 59 (4) :1366-1380.
|
[24]SINGH R, KAUSHIK S, WANG Y, et al.Autophagy regulates lipid metabolism[J].Nature, 2009, 458 (7242) :1131-1135.
|
[25]DING WX, LI M, CHEN X, et al.Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice[J].Gastroenterology, 2010, 139 (5) :1740-1752.
|
[26]LIU K, CZAJA MJ.Regulation of lipid stores and metabolism by lipophagy[J].Cell Death Differ, 2013, 20 (1) :3-11.
|
[27]LI Y, HAI J, LI L, et al.Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after nonalcoholic fatty liver disease development[J].Endocrine, 2013, 43 (2) :376-386.
|
[28]WINDER WW, HARDIE DG.AMP-activated protein kinase, a metabolic master switch:possible roles in type 2 diabetes[J].Am J Physiol, 1999, 277 (1 Pt 1) :e1-e10.
|
[29]YIN XM, DING WX, GAO W.Autophagy in the liver[J].Hepatology, 2008, 47 (5) :1773-1785.
|
[30]BARAZZONI R, SEMOLIC A, CATTIN MR, et al.Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats[J].Obesity (Silver Spring) , 2014, 22 (1) :170-177.
|
[31]SHOJI-KAWATA S, SUMPTER R, LEVENO M, et al.Identification of a candidate therapeutic autophagy-inducing peptide[J].Nature, 2013, 494 (7436) :201-206.
|
[32]LIN CW, ZHANG H, LI M, et al.Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in Mice[J].J Hepatol, 2013, 58 (5) :993-999.
|
[33]SINHA RA, YOU SH, ZHOU J, et al.Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy[J].J Clin Invest, 2012, 122 (7) :2428-2438.
|
[34]NI HM, WILLIAMS JA, YANG H, et al.Targeting autophagy for the treatment of liver diseases[J].Pharmacol Res, 2012, 66 (6) :463-474.
|
[35]CODOGNO P, MEIJER AJ.Autophagy in the liver[J].J Hepatol, 2013, 59 (2) :389-391.
|
[36]DING WX.Induction of autophagy, a promising approach for treating liver injury[J].Hepatology, 2014, 59 (1) :340-343.
|
[37]LOMONACO R, SUNNY NE, BRIL F, et al.Nonalcoholic fatty liver disease:current issues and novel treatment approaches[J].Drugs, 2013, 73 (1) :1-14.
|